Related Experiment Video
Updated: Dec 29, 2025
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
308
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
Sang Hyoung Park1, Jae Cheol Park1, Milan Lukas2
1Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Intestinal Research
|February 5, 2020
Summary
Biosimilars offer a cost-effective alternative for managing inflammatory bowel diseases (IBD), showing comparable efficacy and safety to original biologics. Their adoption is increasing, impacting healthcare costs positively.
Area of Science:
- Gastroenterology and Immunology
- Pharmacoeconomics
Background:
- Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic, immune-mediated conditions with rising global incidence and prevalence.
- Increasing IBD prevalence leads to escalating healthcare expenditures, highlighting the need for cost-effective treatments.
Purpose of the Study:
- To evaluate the role and impact of biosimilars in the management of inflammatory bowel diseases (IBD).
- To address concerns regarding the efficacy, safety, and interchangeability of biosimilars compared to originator biologic agents.
Main Methods:
- Review of prospective observations and phase III/IV clinical trials assessing biosimilarity to original biologic agents.
- Analysis of reported budget impact and physician/patient perceptions regarding biosimilar use in IBD.
Main Results:
- Evidence from trials supports the efficacy, safety, and interchangeability of biosimilars with original biologics for IBD treatment.
- Despite initial reluctance, biosimilars have demonstrated a positive budget impact in various healthcare systems.
Conclusions:
- Biosimilars represent a promising, lower-cost therapeutic option for IBD, with profiles similar to original biologics.
- Further consideration and education are necessary to facilitate the integration of biosimilars into IBD management strategies.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
390
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
390
01:28Drug Products: Biologics, Biosimilars and Interchangeables
189
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
189
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
393
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
393
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
406
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
406
01:29Drugs for Treatment of Ulcerative Colitis in IBD
387
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
387
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
565
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
565